Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of VB-111 plus paclitaxel versus placebo plus paclitaxel in platinum-resistant recurrent ovarian cancer
MOH_2017-11-15_001872Phase 3Completed
- Sponsor
- VBL Therapeutics
- Start
- Jul 2017
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Ofranergene obadenovec + paclitaxel with Control: Placebo + paclitaxel (2 arms). Started Jul 2017; status: completed.
02
Drugs
ofranergene obadenovec
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on MOH_2017-11-15_001872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-15_001872.